O	0	3	The
O	4	11	Patient
O	11	12	'
O	12	13	s
O	14	25	Anastrozole
O	26	36	Compliance
O	37	39	to
O	40	47	Therapy
O	48	49	(
O	49	53	PACT
O	53	54	)
O	55	62	Program
O	62	63	:
O	64	65	a
O	66	76	randomized
O	76	77	,
O	78	80	in
O	80	81	-
O	81	89	practice
O	90	95	study
O	96	98	on
O	99	102	the
O	103	109	impact
O	110	112	of
O	113	114	a
B-intervention	115	127	standardized
I-intervention	128	139	information
I-intervention	140	147	program
O	148	150	on
O	151	162	persistence
O	163	166	and
O	167	177	compliance
O	178	180	to
O	181	189	adjuvant
O	190	199	endocrine
O	200	207	therapy
O	208	210	in
O	211	225	postmenopausal
O	226	231	women
O	232	236	with
O	237	242	early
O	243	249	breast
O	250	256	cancer
O	256	257	.

O	258	268	Compliance
O	269	272	and
O	273	284	persistence
O	285	288	are
O	289	294	often
O	295	305	overlooked
O	306	308	in
O	309	317	adjuvant
O	318	324	breast
O	325	331	cancer
O	332	341	treatment
O	341	342	.

O	343	347	PACT
O	348	351	was
O	352	353	a
O	354	365	prospective
O	365	366	,
O	367	378	multicenter
O	378	379	,
O	380	390	randomized
O	390	391	,
O	392	396	open
O	396	397	,
O	398	406	parallel
O	406	407	-
O	407	412	group
O	413	418	study
O	419	428	assessing
O	429	436	whether
O	437	448	educational
O	449	458	materials
O	459	460	(
O	460	463	EMs
O	463	464	)
O	465	473	enhanced
O	474	484	compliance
O	485	489	with
O	490	499	aromatase
O	500	509	inhibitor
O	510	511	(
O	511	513	AI
O	513	514	)
O	515	522	therapy
O	523	525	in
O	526	540	postmenopausal
O	541	546	women
O	547	551	with
O	552	557	early
O	557	558	,
O	559	566	hormone
O	566	567	-
O	567	575	receptor
O	575	576	-
O	576	584	positive
O	585	586	(
O	586	588	HR
O	588	589	+
O	589	590	)
O	591	597	breast
O	598	604	cancer
O	604	605	.

O	606	609	The
O	610	617	primary
O	618	621	end
O	622	628	points
O	629	633	were
B-outcome-Measure	634	644	compliance
O	645	646	(
O	646	656	proportion
O	657	663	taking
O	664	665	≥
O	666	668	80
O	668	669	%
O	670	681	anastrozole
O	681	682	)
O	683	685	at
O	686	688	12
O	689	695	months
O	696	699	and
B-outcome-Measure	700	711	persistence
O	712	713	(
O	713	723	proportion
O	724	733	reporting
O	734	745	anastrozole
O	746	752	intake
O	753	759	during
O	760	763	the
O	764	769	study
O	770	776	period
O	776	777	)
O	777	778	.

B-total-participants	779	783	Four
I-total-participants	784	792	thousand
I-total-participants	793	798	eight
I-total-participants	799	806	hundred
I-total-participants	807	810	and
I-total-participants	811	816	forty
I-total-participants	816	817	-
I-total-participants	817	821	four
O	822	830	patients
O	831	835	were
O	836	844	randomly
O	845	853	assigned
O	854	855	1
O	855	856	:
O	856	857	1
O	858	860	to
O	861	868	receive
B-control	869	877	standard
I-control	878	885	therapy
O	886	888	or
O	889	897	standard
O	898	905	therapy
O	906	910	with
O	911	914	EMs
O	914	915	.

O	916	921	There
O	922	925	was
O	926	928	no
O	929	939	difference
O	940	947	between
O	948	952	arms
O	953	955	in
B-outcome	956	966	compliance
O	967	968	(
O	968	969	N
O	970	971	=
O	972	976	2740
O	976	977	;
B-cv-bin-percent	978	980	88
I-cv-bin-percent	980	981	.
I-cv-bin-percent	981	982	5
I-cv-bin-percent	982	983	%
O	983	984	/
B-iv-bin-percent	984	986	88
I-iv-bin-percent	986	987	.
I-iv-bin-percent	987	988	8
I-iv-bin-percent	988	989	%
O	989	990	,
O	991	1003	respectively
O	1003	1004	,
O	1005	1006	P
O	1007	1008	=
O	1009	1010	0
O	1010	1011	.
O	1011	1013	81
O	1013	1014	)
O	1015	1017	or
B-outcome	1018	1029	persistence
I-outcome	1030	1035	rates
O	1036	1037	(
O	1037	1038	N
O	1039	1040	=
O	1041	1045	2740
O	1045	1046	;
B-cv-bin-percent	1047	1049	40
I-cv-bin-percent	1049	1050	.
I-cv-bin-percent	1050	1051	5
I-cv-bin-percent	1051	1052	%
O	1052	1053	/
B-iv-bin-percent	1053	1055	43
I-iv-bin-percent	1055	1056	.
I-iv-bin-percent	1056	1057	0
I-iv-bin-percent	1057	1058	%
O	1058	1059	,
O	1060	1072	respectively
O	1072	1073	,
O	1074	1075	P
O	1076	1077	=
O	1078	1079	0
O	1079	1080	.
O	1080	1082	18
O	1082	1083	)
O	1083	1084	.

O	1085	1093	Modified
O	1094	1097	end
O	1098	1103	point
O	1104	1112	analyses
O	1113	1118	found
O	1119	1121	no
O	1122	1133	differences
O	1134	1136	in
B-outcome	1137	1147	compliance
O	1148	1155	between
O	1156	1160	arms
O	1161	1166	based
O	1167	1169	on
O	1170	1173	the
O	1174	1188	classification
O	1189	1191	of
O	1191	1192	:
O	1193	1194	(
O	1194	1195	i
O	1195	1196	)
B-outcome	1197	1205	patients
I-outcome	1206	1210	with
I-outcome	1211	1218	missing
I-outcome	1219	1232	documentation
I-outcome	1233	1235	or
I-outcome	1236	1242	follow
I-outcome	1242	1243	-
I-outcome	1243	1245	up
I-outcome	1246	1251	visit
O	1252	1253	<
O	1253	1254	9
O	1255	1261	months
O	1262	1264	as
O	1265	1268	non
O	1268	1269	-
O	1269	1278	compliant
O	1279	1280	(
O	1280	1281	N
O	1282	1283	=
O	1284	1288	4397
O	1288	1289	,
O	1290	1291	P
O	1292	1293	=
O	1294	1295	0
O	1295	1296	.
O	1296	1298	15
O	1298	1299	)
O	1299	1300	;
O	1301	1302	(
O	1302	1304	ii
O	1304	1305	)
B-outcome	1306	1314	patients
I-outcome	1315	1319	with
I-outcome	1320	1325	early
I-outcome	1326	1327	(
I-outcome	1327	1328	≤
I-outcome	1329	1332	292
I-outcome	1333	1337	days
I-outcome	1337	1338	)
I-outcome	1339	1341	12
I-outcome	1341	1342	-
I-outcome	1342	1347	month
I-outcome	1348	1354	follow
I-outcome	1354	1355	-
I-outcome	1355	1357	up
I-outcome	1358	1371	documentation
I-outcome	1372	1380	excluded
O	1381	1382	(
O	1382	1383	N
O	1384	1385	=
O	1386	1390	4091
O	1390	1391	,
O	1392	1393	P
O	1394	1395	=
O	1396	1397	0
O	1397	1398	.
O	1398	1400	19
O	1400	1401	)
O	1401	1402	;
O	1403	1404	(
O	1404	1407	iii
O	1407	1408	)
B-outcome	1409	1417	patients
I-outcome	1418	1426	reaching
I-outcome	1427	1428	≥
I-outcome	1429	1431	80
I-outcome	1431	1432	%
I-outcome	1433	1443	compliance
O	1444	1450	during
O	1451	1461	individual
O	1462	1468	follow
O	1468	1469	-
O	1469	1471	up
O	1472	1474	as
O	1475	1484	compliant
O	1485	1486	(
O	1486	1487	N
O	1488	1489	=
O	1490	1494	4397
O	1494	1495	,
O	1496	1497	P
O	1498	1499	=
O	1500	1501	0
O	1501	1502	.
O	1502	1504	26
O	1504	1505	)
O	1505	1506	.

O	1507	1515	Modified
O	1516	1527	persistence
O	1528	1536	analyses
O	1537	1542	found
O	1543	1545	no
O	1546	1556	difference
O	1557	1564	between
O	1565	1569	arms
O	1570	1571	(
O	1571	1572	N
O	1573	1574	=
O	1575	1579	4397
O	1579	1580	,
O	1581	1582	P
O	1583	1584	=
O	1585	1586	0
O	1586	1587	.
O	1587	1589	37
O	1589	1590	)
O	1590	1591	.

O	1592	1600	Addition
O	1601	1603	of
O	1604	1607	EMs
O	1608	1610	to
O	1611	1619	standard
O	1620	1627	therapy
O	1628	1631	did
O	1632	1635	not
O	1636	1649	significantly
O	1650	1656	affect
O	1657	1667	compliance
O	1668	1671	and
O	1672	1683	persistence
O	1684	1688	with
O	1689	1697	adjuvant
O	1698	1709	anastrozole
O	1709	1710	.

O	1711	1725	CLINICALTRIALS
O	1726	1728	ID
O	1728	1729	:
O	1730	1741	NCT00555867
O	1741	1742	.
